Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

AADI

Aadi Bioscience Inc

Dec 13 • 04:00PM ET

2.41

Dollar change 0.00
Percentage change 0.00	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD BMRN RARE ARGX AGIO AFMD AMRN ATRA ADAP ONVO

| Held by: VTI VXF IWC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.29	Insider Own	18.48%	Shs Outstand	24.61M	Perf Week	-0.41%
Market Cap	59.40M	Forward P/E	-	EPS next Y	-0.30	Insider Trans	-2.77%	Shs Float	20.09M	Perf Month	11.06%
Income	-61.69M	PEG	-	EPS next Q	-0.21	Inst Own	48.67%	Short Float	1.12%	Perf Quarter	28.19%
Sales	25.07M	P/S	2.37	EPS this Y	22.54%	Inst Trans	14.08%	Short Ratio	1.90	Perf Half Y	42.60%
Book/sh	2.80	P/B	0.86	EPS next Y	84.13%	ROA	-54.75%	Short Interest	0.22M	Perf Year	-55.04%
Cash/sh	2.54	P/C	0.95	EPS next 5Y	-	ROE	-65.95%	52W Range	1.21 - 5.54	Perf YTD	19.31%
Dividend Est.	-	P/FCF	-	EPS past 5Y	11.87%	ROI	-88.77%	52W High	-56.50%	Beta	0.72
Dividend TTM	-	Quick Ratio	4.54	Sales past 5Y	225.26%	Gross Margin	87.39%	52W Low	99.17%	ATR (14)	0.11
Dividend Ex-Date	-	Current Ratio	4.89	EPS Y/Y TTM	3.12%	Oper. Margin	-253.63%	RSI (14)	60.20	Volatility	4.33% 4.94%
Employees	89	Debt/Eq	0.01	Sales Y/Y TTM	7.80%	Profit Margin	-246.06%	Recom	3.00	Target Price	2.00
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	23.31%	Payout	-	Rel Volume	0.69	Prev Close	2.41
Sales Surprise	9.36%	EPS Surprise	-0.55%	Sales Q/Q	21.03%	Earnings	Nov 06 BMO	Avg Volume	117.71K	Price	2.41
SMA20	3.46%	SMA50	11.51%	SMA200	27.71%	Trades		Volume	81,684	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-27-24	Downgrade	Piper Sandler	Overweight → Neutral	$5 → $1.75
Aug-21-24	Downgrade	TD Cowen	Buy → Hold
Aug-21-24	Downgrade	Jefferies	Buy → Hold	$11 → $1.50
Dec-15-23	Downgrade	H.C. Wainwright	Buy → Neutral
Jan-11-22	Initiated	Jefferies	Buy	$45
Oct-01-21	Initiated	Cowen	Outperform
Sep-14-21	Initiated	Ladenburg Thalmann	Buy	$51
Sep-08-21	Initiated	Piper Sandler	Overweight	$45

Nov-06-24 08:00AM	Aadi Bioscience Announces Financial Results for the Third Quarter 2024 and Provides Corporate Update (PR Newswire) +6.53%
Oct-30-24 04:05PM	Aadi Bioscience to Report Third Quarter 2024 Results and Corporate Update (PR Newswire)
Aug-20-24 05:00PM	Aadi Bioscience Provides PRECISION1 Trial and Corporate Updates (PR Newswire)
Aug-07-24 08:00AM	Aadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate Update (PR Newswire)
Jul-31-24 04:05PM	Aadi Bioscience to Report Second Quarter 2024 Results and Corporate Update (PR Newswire)
01:07PM	Loading…
Jul-05-24 01:07PM	3 Russell 2000 Stocks to Sell in July Before They Crash & Burn (InvestorPlace)
May-29-24 04:05PM	Aadi Bioscience to Participate in the Jefferies Healthcare Conference (PR Newswire) -6.38%
May-23-24 05:30PM	Aadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual Meeting (PR Newswire) -5.70%
May-09-24 01:52PM	Aadi Bioscience, Inc. (NASDAQ:AADI) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-08-24 12:53PM	AADI Stock Earnings: Aadi Bioscience Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) -12.80%
08:00AM	Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update (PR Newswire)
May-01-24 08:01AM	Aadi Bioscience to Report First Quarter 2024 Results and Corporate Update (PR Newswire)
Apr-09-24 08:00AM	Aadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual Meeting (PR Newswire)
Apr-03-24 09:40AM	Is Aadi Bioscience (AADI) Stock Outpacing Its Medical Peers This Year? (Zacks)
Mar-18-24 09:40AM	Is Aadi Bioscience (AADI) Outperforming Other Medical Stocks This Year? (Zacks)
08:00AM	Loading…
Mar-17-24 08:00AM	Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO) (PR Newswire)
Mar-15-24 10:43AM	Aadi Bioscience, Inc. (NASDAQ:AADI) Q4 2023 Earnings Call Transcript (Insider Monkey) +5.85%
Mar-13-24 09:05AM	Aadi Bioscience, Inc. (AADI) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +11.34%
08:00AM	Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Corporate Update (PR Newswire)
Mar-06-24 08:00AM	Aadi Bioscience to Report Fourth Quarter and Full-Year 2023 Results and Corporate Update (PR Newswire)
Mar-05-24 04:30PM	Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024 (PR Newswire) -13.35%
Mar-01-24 04:08PM	Aadi Bioscience Announces Publication of Long-Term Efficacy and Safety Data Further Supporting FYARRO for the Treatment of Malignant PEComa (PR Newswire) +26.82%
Feb-26-24 04:05PM	Aadi Bioscience to Present at the TD Cowen 44th Annual Healthcare Conference (PR Newswire)
Jan-26-24 04:05PM	Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium (PR Newswire)
Jan-19-24 04:05PM	Aadi Bioscience Announces Poster Presentations at the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal (GI) Cancers Symposium (PR Newswire)
Dec-15-23 09:14AM	Why Is Aadi Bioscience (AADI) Stock Down 56% Today? (InvestorPlace) -56.42%
Dec-14-23 04:05PM	Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations (PR Newswire)
Nov-08-23 08:46AM	Aadi Bioscience Q3 Loss Per Share Narrows (RTT News)
08:00AM	Aadi Bioscience Reports Financial Results for the Third Quarter 2023 and Provides Corporate Update (PR Newswire)
Nov-06-23 04:05PM	Aadi Bioscience to Participate in Jefferies London Healthcare Conference (PR Newswire)
04:05PM	Loading…
Nov-01-23 04:05PM	Aadi Bioscience to Report Third Quarter 2023 Results and Operational Update (PR Newswire) +6.48%
Oct-19-23 04:05PM	Aadi Bioscience Announces Poster Presentations on Nab-Sirolimus at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global Meeting (PR Newswire)
Oct-12-23 04:05PM	Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (PR Newswire)
Oct-05-23 04:05PM	Aadi Bioscience Announces Poster Presentations at the North American Neuroendocrine Tumor Society (NANETS) 2023 Multidisciplinary NET Medical Symposium (PR Newswire)
Oct-03-23 04:05PM	Aadi Bioscience Grants New CEO Dave Lennon, Ph.D. Inducement Award Under Nasdaq Listing Rule 5635 (c)(4) (PR Newswire) -6.51%
Oct-02-23 08:00AM	Aadi Bioscience Appoints Dave Lennon, Ph.D. as President and Chief Executive Officer (PR Newswire) -11.16%
Sep-20-23 04:30PM	Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (PR Newswire)
Sep-05-23 08:00AM	Aadi Bioscience to Participate at Upcoming Investor Conferences (PR Newswire) -6.31%
Aug-09-23 08:00AM	Aadi Bioscience Announces Financial Results for the Second Quarter 2023 and Provides Corporate Update (PR Newswire) -6.85%
Aug-02-23 08:00AM	Aadi Bioscience to Report Second Quarter 2023 Results and Operational Update (PR Newswire)
May-25-23 05:30PM	Aadi Bioscience Announces Presentations at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (PR Newswire)
May-23-23 08:00AM	Aadi Bioscience to Participate in Upcoming Investor Events (PR Newswire)
May-10-23 08:00AM	Aadi Bioscience Announces Financial Results and Operational Update for the First Quarter 2023 and Provides Update on PRECISION 1 Tumor Agnostic Trial (PR Newswire) -16.61%
May-03-23 08:00AM	Aadi Bioscience to Report First Quarter 2023 Results and Operational Update (PR Newswire)
Apr-26-23 04:05PM	Aadi Bioscience Announces Multiple Presentations on nab-Sirolimus at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting (PR Newswire)
Apr-14-23 01:00PM	Aadi Bioscience to Present Multiple Posters on nab-Sirolimus at the 2023 American Association for Cancer Research (AACR) Annual Meeting (PR Newswire)
Apr-06-23 04:30PM	Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2023 (PR Newswire)
Mar-28-23 08:00AM	Aadi Bioscience Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Corporate Update (PR Newswire) -5.52%
Mar-27-23 08:00AM	Aadi Bioscience Appoints Mohammad Hirmand, M.D. to Board of Directors (PR Newswire)
Mar-26-23 02:00PM	Aadi Bioscience Presents Clinical Data from PRECISION 1 and AMPECT Trials at the Society of Gynecological Oncology (SGO) Annual Meeting on Women's Cancer (PR Newswire)
Mar-15-23 08:00AM	Aadi Bioscience to Report Fourth Quarter and Full-Year 2022 Results and Corporate Update (PR Newswire)
Mar-03-23 08:00AM	Aadi Bioscience Announces Leadership Transition (PR Newswire) -14.51%
Feb-22-23 08:00AM	Aadi Bioscience to Present at the 43rd Annual Cowen Healthcare Conference (PR Newswire)
Nov-17-22 08:00AM	Aadi Bioscience Presents PRECISION 1 Trial in Progress Poster and AMPECT Trial Final Analysis at the Connective Tissue Oncology Society (CTOS) 2022 Annual Meeting (PR Newswire)
Nov-09-22 08:00AM	Aadi Bioscience Announces Financial Results for the Third Quarter of 2022 and Provides Corporate Update (PR Newswire)
Nov-08-22 04:00PM	Aadi Bioscience Announces Planned Leadership Transition (PR Newswire)
Nov-03-22 08:00AM	Aadi Bioscience to Present at Upcoming Investor Conferences (PR Newswire)
Oct-27-22 08:00AM	Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR Symposium (PR Newswire)
Oct-12-22 08:01AM	Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR Symposium (PR Newswire)
08:00AM	Mirati Therapeutics and Aadi Bioscience Partner to Evaluate the Combination of Adagrasib with Nab-sirolimus in Patients with Advanced Non-Small Cell Lung Cancer and Other Solid Tumors with a KRAS[G12C] Mutation (PR Newswire)
Sep-22-22 04:01PM	Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing (PR Newswire) +8.06%
Sep-01-22 08:00AM	Aadi Bioscience Announces Participation in Upcoming September Investor Conferences (PR Newswire)
Aug-10-22 08:00AM	Aadi Bioscience Announces Financial Results for the Second Quarter of 2022 and Provides Corporate Update (PR Newswire)
Aug-04-22 06:21AM	Is Aadi Bioscience, Inc. (NASDAQ:AADI) Popular Amongst Insiders? (Simply Wall St.)
Jul-28-22 08:30AM	Aadi Bioscience to Report Second Quarter 2022 Results and Corporate Update (PR Newswire)
Jun-23-22 08:00AM	Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes (GlobeNewswire) +6.00%
Jun-01-22 08:00AM	Aadi Bioscience to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-31-22 08:00AM	Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications (GlobeNewswire)
May-26-22 05:10PM	Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Presented at 2022 ASCO Annual Meeting (GlobeNewswire) +5.11% +6.88%
May-18-22 07:00AM	Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) -7.91%
May-12-22 08:32AM	UPDATE -- Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update (GlobeNewswire) +9.33%
07:00AM	Aadi Bioscience Reports First Quarter 2022 Financial Results and Provides a Corporate Update (GlobeNewswire)
May-09-22 08:00AM	Aadi Bioscience Announces Collaborations with Next Generation Sequencing Leaders (GlobeNewswire) -10.81%
May-04-22 08:00AM	Aadi Bioscience Announces Unique Permanent J-code Issued for FYARRO from Centers for Medicare and Medicaid Services (GlobeNewswire)
Apr-28-22 05:07PM	Aadi Bioscience to Announce First Quarter 2022 Financial Results on May 12, 2022 (GlobeNewswire) -5.38%
Apr-18-22 08:00AM	Aadi Bioscience to Participate at the Jefferies Biotech on the Bay Summit (GlobeNewswire) -5.81%
Apr-08-22 01:09PM	Aadi Bioscience Announces Data Presentation on incidence of TSC1 and TSC2 Alterations in Advanced Cancers at the Annual Meeting of the American Association for Cancer Research (AACR) (GlobeNewswire)
Apr-01-22 05:13AM	Top Biotech Stocks for Q2 2022 (Investopedia)
Mar-31-22 02:45PM	Aadi Bioscience Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes (GlobeNewswire)
Mar-17-22 07:00AM	Aadi Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update (GlobeNewswire) +8.40%
Mar-01-22 07:00AM	Aadi Bioscience to Participate in Panel Discussion on Tumor-Agnostic Development at Cowens 42nd Annual Health Care Conference (GlobeNewswire)
Feb-25-22 04:41AM	Here's What Aadi Bioscience, Inc.'s (NASDAQ:AADI) Shareholder Ownership Structure Looks Like (Simply Wall St.)
Feb-23-22 07:00AM	Aadi Bioscience Announces U.S. Commercial Launch and Availability of FYARRO for the Treatment of Adult Patients with Locally Advanced Unresectable or Metastatic Malignant PEComa (GlobeNewswire)
Jan-04-22 04:30PM	Aadi Bioscience to Present at 2022 H.C. Wainwright BioConnect Virtual Conference (GlobeNewswire) -7.35%
Dec-28-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com)
Dec-23-21 12:38PM	Rtw Investments, Lp Buys Thermo Fisher Scientific Inc, Penumbra Inc, Tenaya Therapeutics Inc, ... (GuruFocus.com)
Dec-21-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com)
Dec-16-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com)
Dec-08-21 09:38AM	Opaleye Management Inc. Buys Semler Scientific Inc, Keros Therapeutics Inc, Crinetics ... (GuruFocus.com)
Nov-27-21 06:01AM	Companies Like Aadi Bioscience (NASDAQ:AADI) Are In A Position To Invest In Growth (Simply Wall St.)
06:01AM	Some Analysts Just Cut Their Aadi Bioscience, Inc. (NASDAQ:AADI) Estimates (Simply Wall St.)
Nov-23-21 04:22PM	Aadi Bioscience Pops And Then Tumbles After Snagging Its First FDA Approval (Investor's Business Daily) -5.84%
06:00AM	Aadi Bioscience Announces FDA Approval of its First Product FYARRO for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa) (GlobeNewswire)
Nov-15-21 08:00AM	UPDATE Aadi Bioscience Presents Two Abstracts on FYARRO (nab-Sirolimus) at the Annual Meeting of the Connective Tissue Oncology Society (CTOS) (GlobeNewswire) +7.31%
Nov-13-21 01:35PM	Aadi Bioscience Presents Two Abstracts on FYARRO (nab-Sirolimus) at the Annual Meeting of the Connective Tissue Oncology Society (CTOS) (GlobeNewswire)
Nov-10-21 07:00AM	Aadi Reports Third Quarter 2021 Financial Results and Provides Business Update (GlobeNewswire) -16.93%
Nov-09-21 08:00AM	Aadi Bioscience to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-01-21 04:05PM	Aadi Bioscience Appoints Scott Giacobello as Chief Financial Officer (GlobeNewswire)
Oct-25-21 08:00AM	Aadi Bioscience Appoints Loretta Itri as Chief Medical Officer (GlobeNewswire)
Oct-22-21 08:00AM	Aadi Bioscience Announces Publication of its Phase 2 Registrational (AMPECT) Trial of nab-Sirolimus in Patients with Malignant Perivascular Epithelioid Cell Tumors in the Journal of Clinical Oncology (GlobeNewswire)

Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. It develops precision therapies for genetically-defined cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes. The company was founded by Neil Desai in November 2007 and is headquartered in Los Angeles, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lennon David James	CHIEF EXECUTIVE OFFICER	Oct 02 '24	Option Exercise	0.00	32,558	0	32,558	Oct 03 07:03 PM
Lennon David James	CHIEF EXECUTIVE OFFICER	Oct 03 '24	Sale	1.94	9,689	18,797	22,869	Oct 03 07:03 PM
Lennon David James	Officer	Oct 03 '24	Proposed Sale	1.94	9,689	18,797		Oct 03 07:01 PM
Desai Neil	EXECUTIVE CHAIRMAN	Sep 03 '24	Sale	1.71	40,000	68,316	1,171,543	Sep 05 05:55 PM
Desai Neil	Officer	Sep 03 '24	Proposed Sale	1.79	120,000	214,416		Sep 03 10:40 AM
Desai Neil	EXECUTIVE CHAIRMAN	Aug 02 '24	Sale	1.41	18,933	26,705	1,217,195	Aug 05 06:49 PM
Desai Neil	EXECUTIVE CHAIRMAN	Aug 01 '24	Sale	1.50	15,415	23,055	1,236,128	Aug 05 06:49 PM
Desai Neil	EXECUTIVE CHAIRMAN	Aug 05 '24	Sale	1.34	5,652	7,595	1,211,543	Aug 05 06:49 PM
Desai Neil	EXECUTIVE CHAIRMAN	Jul 01 '24	Sale	1.45	31,348	45,605	1,260,195	Jul 02 06:37 PM
Desai Neil	EXECUTIVE CHAIRMAN	Jul 02 '24	Sale	1.34	8,652	11,612	1,251,543	Jul 02 06:37 PM
Desai Neil	EXECUTIVE CHAIRMAN	Jun 03 '24	Sale	1.81	19,775	35,765	1,311,768	Jun 05 04:25 PM
Desai Neil	EXECUTIVE CHAIRMAN	Jun 04 '24	Sale	1.77	20,225	35,746	1,291,543	Jun 05 04:25 PM
Desai Neil	EXECUTIVE CHAIRMAN	May 01 '24	Sale	1.93	40,000	77,184	1,331,543	May 01 08:50 PM
Desai Neil	EXECUTIVE CHAIRMAN	Apr 02 '24	Sale	2.23	22,228	49,513	1,371,543	Apr 03 04:49 PM
Desai Neil	EXECUTIVE CHAIRMAN	Apr 01 '24	Sale	2.31	17,772	41,101	1,393,771	Apr 03 04:49 PM
Desai Neil	EXECUTIVE CHAIRMAN	Mar 01 '24	Sale	1.97	27,036	53,226	1,426,507	Mar 04 07:22 PM
Desai Neil	EXECUTIVE CHAIRMAN	Mar 04 '24	Sale	2.10	14,964	31,415	1,411,543	Mar 04 07:22 PM
Desai Neil	Executive Chairman	Feb 01 '24	Sale	1.74	42,000	73,269	1,453,543	Feb 02 05:04 PM
Desai Neil	Executive Chairman	Jan 02 '24	Sale	2.06	42,000	86,549	1,495,543	Jan 02 07:48 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AADI

Aadi Bioscience Inc

Upgrade your FINVIZ experience